Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRT543

Small molecule · Inhibitor of protein arginine methyltransferase 5 (PRMT5) · developed by Prelude Therapeutics

Phase 1 Most advanced trial (none active)
PRLD Developer
1 Registered trials

What is PRT543?

PRT543 is an orally available small molecule that selectively binds the substrate recognition site of PRMT5 and inhibits its methyltransferase activity, reducing methylated arginine on histones H2A, H3 and H4. It is being studied in relapsed or refractory solid tumors, lymphomas, myeloid malignancies and adenoid cystic carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
protein arginine methyltransferase 5 (PRMT5)
Mechanism
Inhibitor of protein arginine methyltransferase 5 (PRMT5)
Pathways
histone arginine methylation, gene expression regulation of cellular proliferation
Therapy area
Oncology
Developer
Prelude Therapeutics Incorporated (PRLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03886831 Phase 1 Relapsed/Refractory Advanced Solid Tumors Completed PRLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Adenoid Cystic CarcinomaRefractory Chronic Myelomonocytic LeukemiaRelapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory Advanced Solid TumorsRelapsed/Refractory Diffuse Large B-cell LymphomaRelapsed/Refractory Mantle Cell LymphomaRelapsed/Refractory MyelodysplasiaRelapsed/Refractory Myelofibrosis

Other drugs acting on PRMT5

More from Prelude Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.

Follow PRLD, the company behind PRT543

See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.